The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNuformix Share News (NFX)

Share Price Information for Nuformix (NFX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.175
Bid: 0.17
Ask: 0.18
Change: -0.01 (-5.41%)
Spread: 0.01 (5.882%)
Open: 0.185
High: 0.00
Low: 0.00
Prev. Close: 0.185
NFX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

WINNERS & LOSERS SUMMARY: 7digital Warns Of Need For Capital Raise

Tue, 09th Apr 2019 10:46

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Tuesday.----------FTSE 100 - WINNERS----------Anglo American, up 0.5%. The miner said its De Beers rough diamond sales in the third sales cycle of 2019 were about 10% higher than the year prior amid "stable" demand. Its third cycle sales in 2019 - as of Tuesday - stood at a provisional USD575 million. This was 9.7% higher than the USD524 million sales reported in the third cycle of 2018 and 16% up on the USD496 million sales reported for the second cycle of 2019.----------FTSE 100 - LOSERS----------Severn Trent, down 2.0%. JPMorgan downgraded the water company to Neutral from Overweight. ----------FTSE 250 - WINNERS----------NewRiver REIT, up 2.5%. The trust declared a fourth-quarter dividend of 5.4 pence per share, which is a 3% increase on the fourth quarterly dividend of 5.25 pence the prior year.----------FTSE 250 - LOSERS----------Pennon Group, down 2.0%. JPMorgan cut the utility stock to Neutral from Overweight. Hays, down 1.5%. Morgan Stanley downgraded the recruiter to Equal Weight from Overweight. Go-Ahead Group, 1.0%. HSBC lowered its rating on the transport operator to Hold from Buy. ----------OTHER MAIN MARKET AND AIM - WINNERS----------Nuformix, up 60%. The pharmaceutical firm said it has signed a cannabinoid therapeutics agreement worth up to GBP51 million with private Canadian company Ebers Tech. The development, licensing and commercialisation agreement contains as much as GBP51 million of upfront, research and development, and milestone payments as well as long-term royalties of 20% of net sales, Nuformix said. Under the agreement, Ebers can use Nuformix's technology platforms to bring therapeutic cannabinoid products to market. Ebers is backed by financial sector leaders with connections to the US cannabinoid market. Nuformix is expecting "a significant upfront payment with further research and development and early-stage milestone payments of up to GBP1 million in 2019. More pre-clinical and milestone payments are likely in 2020 and 2021.Defenx, up 55%. The mobile security software firm said it has signed a software distribution and a software services agreement with majority shareholder BV Tech. The new distribution agreement modifies the terms of a previous deal from 2017. BV Tech - which has a 67% stake in Defenx - now has the sole right to sell Defenx's cyber security products to "bodies within the Italian defence, space, national security or critical infrastructures sector" until the end of 2023. For this, BV Tech will pay EUR1.0 million in three instalments before the end of the first half of 2019 and will also pay a 50% royalty fee to Defenx on any revenue from the sale of its products to clients exceeding EUR5.0 million. BV Tech has also committed, under the distribution agreement, to buy Defenx's products, with a minimal value of EUR1.2 million for a two-year period beginning in January 2019. Prior restrictions have been removed so that BV Tech can now distribute all of Defenx's products on an exclusive basis until the end of 2021. The software services agreement is entirely new. BV Tech will provide software services to Defenx, for which Defenx will pay a maximum of EUR1.2 million. One Media IP Group, up 12%. The digital media content company said annual profit rocketed due to strong streaming demand. The company posted a 63% increase in pretax profit to GBP486,504 for the year ended October 31, 2018, up from GBP297,601 the year before. One Media experienced 17% revenue growth to GBP2.7 million from GBP2.3 million. This was attributed to improved customer demand on streaming platforms, as well as revenue distributions from digital platforms. The company placed some of its music into film and television during its year, with its recording of Chopin's Nocturne Op No 2 in E-Flat Major appearing in Marvel's Daredevil and a new TV series by Jim Carey called 'Kidding'. As at October 31, One Media's cash balance stood at GBP5.6 million versus GBP335,664 the year before. The company added that is "well placed to benefit" from music industry growth and has "a strong pipeline of opportunities".----------OTHER MAIN MARKET AND AIM - LOSERS----------7digital Group, down 63%. The digital music and radio services company warned it requires further funding in the near future to continue trading. Having started a company review, 7digital is taking "a more circumspect" view of its sales pipeline, and it now believes it will need "material" equity or debt funding in the third quarter of 2019. "The board will assess financing options for the company however, it is likely that this would entail significant dilution for shareholders," the company said. As part of the group's new strategy it will no longer be giving a pre-close trading update for 2018, as it decides how to recognise the EUR4.0 million settlement received from MediaMarktSaturn in March. The case related to Media-Saturn subsidiary Juke Entertainment's music service, with Media-Saturn having wanted to end its relationship with 7digital. "The negotiations and ultimate loss of MediaMarktSaturn as a customer prior to John's arrival at the company has diverted management attention and led to disruption within the business during the first quarter as well as having a marked effect on customer sentiment," warned 7digital.Stride Gaming, down 13%. The online gaming operator said its revenue in the first half of its current financial year was lower than expected due to recently implemented regulatory changes. The company expects to report net gaming revenue for the six months to the end of February 5% lower than envisaged due to a disruption from fiscal and regulatory changes in the second half of calendar 2018. However, Stride does now see signs the impact has been largely absorbed and its business model is adjusting accordingly. Looking ahead, the company does not expect to recover the first half revenue shortfall through trading in the second half. Stride expects to report a strong performance from its Stride Together joint venture and is encouraged by further new partnership opportunities.----------

More News
25 Oct 2019 12:27

Nuformix Confirms Japan, Asia Licencing Talks As Shares Surge

Nuformix Confirms Japan, Asia Licencing Talks As Shares Surge

Read more
10 Sep 2019 13:47

Nuformix Chief Financial Officer Kirk Siderman-Wolter Resigns Abruptly

(Alliance News) - Pharmaceutical company Nuformix PLC on Tuesday said Chief Financial Officer and Senior Independent Non-Executive Director Kirk Siderman-Wolter has resigned with immediate company

Read more
9 Sep 2019 11:25

Nuformix, Ebers Tech File Patent For Cannabinoid Cocrystals

(Alliance News) - Pharmaceutical company Nuformix PLC on Monday said it and partner Ebers Tech Inc have filed the first patent in relation to cannabinoid cocrystals.The patented cannabinoid

Read more
6 Sep 2019 12:17

Nuformix Hires Cambridge Interstitial Lung Disease Unit Lead Clinician

(Alliance News) - Nuformix PLC said on Friday it has appointed Muhunthan Thillai to its scientific advisory board with immediate effect.Thillai is the lead clinician for the Cambridge Lung

Read more
18 Jul 2019 11:16

Nuformix Annual Loss Narrows As Revenue Jumps On NXP001 Progress

(Alliance News) - Nuformix PLC on Thursday said its revenue multiplied in its most recently-ended financial year as it has secured its first licensing income from NXP001.NXP001 is one of in

Read more
30 May 2019 10:33

WINNERS & LOSERS SUMMARY: De La Rue Down As CEO Exits And Profit Falls

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Thursday.----------FTSE 100 - LOSERS----------National a

Read more
30 May 2019 10:14

Nuformix Shares Jump On Positive NXP001 Clinical Study Results

LONDON (Alliance News) - Shares in Nuformix PLC surged on Thursday as the company reported positive results in its clinical study of NXP001.Nuformix shares were trading 30% higher at 13.50

Read more
9 Apr 2019 11:25

Nuformix inks cannabinoid therapeutics deal with Ebers Tech

(Sharecast News) - Pharmaceutical development company Nuformix has inked an agreement for cannabinoid therapeutics development, licensing and commercialisation with Canadian outfit Ebers Tech.

Read more
22 Mar 2019 08:50

Nuformix Doses First Patient In NXP001 Anti-Nausea Drug Trial

LONDON (Alliance News) - Nuformix PLC on Friday said it has begun clinical studies for its anti-nausea drug NXP001 and dosed its first patient.Shares in Nuformix were down 4.6% at 2.10 on a

Read more
27 Feb 2019 10:48

MHRA gives go-ahead to Nuformix for human studies

(Sharecast News) - Pharmaceutical development company Nuformix has received approval from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) to begin human pharmacokinetics studies for its lead asset, NXP001, it announced on Wednesday.

Read more
3 Dec 2018 09:53

Nuformix Reports Positive Results From NXP002 Pre-Clinical Trial

LONDON (Alliance News) - Pharmaceutical development firm Nuformix PLC on Monday reported positive results from its completed NXP002 fibrosis programme pre-clinical trial for the treatment of a of

Read more
27 Nov 2018 10:04

Nuformix Expands NXP001 Agreement With Additional Pre-Clinical Study

LONDON (Alliance News) - Pharmaceutical development firm Nuformix PLC said on Tuesday it has expanded its current licensing agreement with partner Newsummit Biopharma for the development of cancer

Read more
14 Sep 2018 10:17

Nuformix Rises As NXP001 Passes "Major" Pre-Clinical Milestone

LONDON (Alliance News) - Shares in pharmaceutical firm Nuformix PLC rose Friday it has received a GBP500,000 payment after its NXP001 product reached a pre-clinical milestone.Nuformix was a

Read more
12 Sep 2018 16:00

UK Shareholder Meetings Calendar - Next 7 Days

Thursday 13 SeptemberBahamas PetroleumFlybe GroupBetter Capital PCCWorldwide 14 UK 17

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.